Drospirenone vs Conjugated Estrogens: side-by-side comparison
Drospirenone (Progestogen with anti-mineralocorticoid and anti-androgen activity) and Conjugated Estrogens (Hormone replacement therapy (estrogen mixture)) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Drospirenone | Conjugated Estrogens |
|---|---|---|
| Therapeutic class | Progestogen with anti-mineralocorticoid and anti-androgen activity | Hormone replacement therapy (estrogen mixture) |
| CAS | 67392-87-4 | 12126-59-9 |
| ATC | G03AA12 | G03CA57 |
| Molecular weight | 366.49 g/mol | 265-272 g/mol (mixture) |
| Brands with this active ingredient | 2 | 1 |
What they share
Drospirenone and Conjugated Estrogens share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Drospirenone acts by a different mechanism than Conjugated Estrogens, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Drospirenone: Drospirenone activates progesterone receptors to suppress ovulation and produce the contraceptive effect when combined with an estrogen. Conjugated Estrogens: Conjugated estrogens act on estrogen receptors throughout the body, restoring estrogen signalling lost after menopause.
Indications compared
Drospirenone: Drospirenone in combination with ethinylestradiol is approved as combined oral contraception, treatment of moderate acne in women requesting contraception, and treatment of premenstrual dysphoric disorder. Conjugated Estrogens: Conjugated estrogens are approved for moderate to severe vasomotor symptoms of menopause, vulvovaginal atrophy due to menopause, osteoporosis prevention in postmenopausal women at significant risk, and primary ovarian fa…
Safety profile
Drospirenone: Common adverse effects include menstrual irregularities, breast tenderness, headache, mood changes and nausea, mostly in the first 2–3 cycles. Conjugated Estrogens: Common adverse effects include nausea, breast tenderness, fluid retention, headache and breakthrough bleeding.
Frequently asked questions
Is Drospirenone better than Conjugated Estrogens? ▾
Drospirenone and Conjugated Estrogens are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Drospirenone and Conjugated Estrogens be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Drospirenone
Products with Conjugated Estrogens
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.